Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage ii or iii her2-negative breast cancer

Clinical Breast Cancer

Volumn 14, Issue 4, 2014, Pages 228-234

  Mrózek, Ewa ^a   Layman, Rachel ^a   Ramaswamy, Bhuvaneswari ^a   Lustberg, Maryam ^a   Vecchione, Andrea ^b   Knopp, Michael V ^c   Shapiro, Charles L ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Carboplatin; Human epidermal growth factor receptor negative breast cancer; Nanoparticle albumin bound paclitaxel; Neoadjuvant chemotherapy; Pathologic complete response

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LUCINE ZIPPER PUTATIVE TUMOR SUPPRESSOR 1 PROTEIN; PACLITAXEL; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ERBB2 PROTEIN, HUMAN; LZTS1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; NANOPARTICLE; TUMOR MARKER;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTRAST ENHANCEMENT; DEPRESSION; DIARRHEA; DRUG INDUCED HEADACHE; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFECTION; INSOMNIA; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; WOUND HEALING IMPAIRMENT; ADJUVANT THERAPY; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; ALBUMINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NANOPARTICLES; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84904647713     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.02.005     Document Type: Article

References (32)

1. H.D. Bear, S. Anderson, and R.E. Smith et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 2006 2019 2027 (Pubitemid 46622110)
2. B. Fisher, J. Bryant, and N. Wolmark et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 1998 2672 2685 (Pubitemid 28363030)
3. J.A. van der Hage, C.J. van der Velde, and J.P. Julien et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902 J Clin Oncol 19 2001 4224 4237
4. A.C. Wolff, D. Berry, and L.A. Carey et al. Research issues affecting preoperative systemic therapy for operable breast cancer J Clin Oncol 26 2008 806 813 (Pubitemid 351264394)
5. J.Y. Pierga, E. Mouret, and V. Laurence et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer: the role of clinical response Eur J Cancer 39 2003 1089 1096 (Pubitemid 36555866)
6. M. Debled, and L. Mauriac Neoadjuvant chemotherapy: are we barking up the right tree? Ann Oncol 21 2010 675 679
7. G. von Minckwitz, M. Untch, and J.U. Blohmer et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 2012 1796 1804
8. A. Gennari, M.P. Sormani, and P. Pronzato et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 2008 14 20 (Pubitemid 351767337)
9. R. Conforti, T. Boulet, and G. Tomasic et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials Ann Oncol 18 2007 1477 1483 (Pubitemid 47365479)
10. M. Colleoni, B.F. Cole, and G. Viale et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer J Clin Oncol 28 2010 2966 2973
11. K. Gelmon, R. Dent, and J.R. Mackey et al. Targeting triple-negative breast cancer: optimising therapeutic outcomes Ann Oncol 23 2012 2223 2234
12. D. Loesch, N. Robert, and L. Asmar et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer J Clin Oncol 20 2002 3857 3864
13. L.G. Estevez, and W.J. Gradishar Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer Clin Cancer Res 10 2004 3249 3261 (Pubitemid 38685428)
14. W.M. Sikov, D.S. Dizon, and R. Stenger et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week Carboplatin and weekly Paclitaxel with or without trastuzumab: a Brown University Oncology Group Study J Clin Oncol 27 2009 4693 4700
15. X.S. Chen, X.Q. Nie, and C.M. Chen et al. Weekly paclitaxel plus carboplatin is an effective non-anthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer Ann Oncol 21 2010 961 967
16. N. Desai, V. Trieu, and Z. Yao et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin Cancer Res 12 2006 1317 1324 (Pubitemid 43342524)
17. N.K. Ibrahim, B. Samuels, and R. Page et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer J Clin Oncol 23 2005 6019 6026
18. W.J. Gradishar, S. Tjulandin, and N. Davidson et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J Clin Oncol 23 2005 7794 7803 (Pubitemid 46657376)
19. H.D. Bear, G. Tang, and P. Rastogi et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer N Engl J Med 366 2012 310 320
20. G. von Minckwitz, H. Eidtmann, and M. Rezai Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer N Engl J Med 366 2012 299 309
21. L.R. Arlinghaus, X. Li, and M. Levy et al. Current and future trends in magnetic resonance imaging assessments of the response of breast tumors to neoadjuvant chemotherapy J Oncol 2010 2010 pii: 919620
22. A. Vecchione, C.M. Croce, and G. Baldassarre Fez1/Lzts1 a new mitotic regulator implicated in cancer development Cell Div 2 2007 24
23. X.X. Wang, Z. Zhu, and D. Su et al. Down-regulation of leucine zipper putative tumor suppressor 1 is associated with poor prognosis, increased cell motility and invasion, and epithelial-to-mesenchymal transition characteristics in human breast carcinoma Hum Pathol 42 2011 1410 1419
24. B. Gerber, S. Loibl, and H. Eidtmann et al. Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44) Ann Oncol 24 2013 2978 2984
25. H.R. Kim, K.H. Jung, and S.A. Im et al. Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905) Ann Oncol 24 2013 1485 1490
26. E.A. Perez, V.J. Suman, and K.M. Rowland et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252 Clin Breast Cancer 6 2005 425 432 (Pubitemid 43078898)
27. C.H. Wu, C.H. Yang, and J.N. Lee et al. Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects Int J Gynecol Cancer 11 2001 295 299 (Pubitemid 32751398)
28. M.L. Citron, D.A. Berry, and C. Cirrincione et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 2003 1431 1439 (Pubitemid 46594092)
29. M. Golshan, J.E. Garber, and R. Gelman et al. Does neoadjuvant bevacizumab increase surgical complications in breast surgery? Ann Surg Oncol 18 2011 733 737
30. M.L. Marinovich, F. Sardanelli, and S. Ciatto et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI Breast 21 2012 669 677
31. V. Roy, B.A. Pockaj, and J.B. Allred et al. A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338 Am J Clin Oncol 36 2013 540 544
32. H.R. Chang, J. Glaspy, and M.A. Allison et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment Cancer 116 2010 4227 4237